NCT05444530View on ClinicalTrials.gov

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

June 24, 2025

Study Completion Date

June 24, 2025

Conditions
Myeloproliferative Neoplasms
Interventions
BIOLOGICAL

VAC85135

Participants will receive VAC85135 as IM injection.

DRUG

Ipilimumab

Participants will receive Ipilimumab as IV infusion.

Trial Locations (7)

33612

Moffitt Cancer Center, Tampa

44195

Cleveland Clinic, Cleveland

77030

MD Anderson Cancer Center, Houston

91010

City of Hope, Duarte

SE1 9RT

Guy's and St Thomas' Hospital, London

M20 4BX

The Christie NHS Foundation Trust Christie Hospital, Manchester

OX3 7LE

Churchill Hospital, Oxford

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Janssen Research & Development, LLC

INDUSTRY

NCT05444530 - A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms | Biotech Hunter | Biotech Hunter